Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of St. John's Wort Ze 117 Prolonged-release vs Immediate-release
NCT02505191Phase 1Completed
- Sponsor
- Max Zeller Söhne
- Start
- Nov 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of St. John's wort extract Ze 117 in major depressive disorder (MDD) (2 arms), sponsored by Max Zeller Söhne. Primary endpoint: Half Value Duration of surrogate markers of the total extract Ze 117 at 3 days. Started Nov 2015; status: completed.
02
Drugs
St. John's wort extract Ze 117
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02505191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02505191.